Literature DB >> 23637292

Comparison of a real-time PCR method with serology and blood smear analysis for diagnosis of human anaplasmosis: importance of infection time course for optimal test utilization.

A M Schotthoefer1, J K Meece, L C Ivacic, P D Bertz, K Zhang, T Weiler, T S Uphoff, T R Fritsche.   

Abstract

Anaplasmosis and ehrlichiosis are emerging tick-borne diseases with clinically similar presentations caused by closely related pathogens. Currently, laboratories rely predominantly on blood smear analysis (for the detection of intracellular morulae) and on serologic tests, both of which have recognized limitations, for diagnostic purposes. We compared the performance of a published real-time PCR assay that incorporates melt curve analysis to differentiate Anaplasma and Ehrlichia species with blood smear and serologic methods in an upper Midwest population. Overall, 38.5% of the specimens selected for evaluation had one or more tests that were positive for anaplasmosis. The PCR positivity for all specimens was maximal (21.2%; 29/137) during the early acute phase of illness (0 to 4 days since illness onset) and significantly less frequent (11.5%; 20/174) during later phases (>4 days since illness onset). All positive specimens were Anaplasma phagocytophilum; no Ehrlichia species were identified. The real-time PCR detected 100% of infections that were detected by blood smear analysis (14/14) and broadened the detection window from a maximum of 14 days for smear positivity to 30 days for PCR. Additional infections were detected by real-time PCR in 12.9% (11/85) of smear-negative patients. There was poor agreement between the real-time PCR assay and serologic test results: 19.8% (19/96) and 13.7% (29/212) of seropositive and -negative patients, respectively, were PCR positive. Seropositivity increased with increasing days of illness, demonstrating that serologic detection methods are best utilized during presumed convalescence. Our results indicate that the optimal performance and utilization of laboratory tests for the diagnosis of anaplasmosis require knowledge regarding time of symptom onset or days of illness.

Entities:  

Mesh:

Year:  2013        PMID: 23637292      PMCID: PMC3697711          DOI: 10.1128/JCM.00347-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  31 in total

Review 1.  Clinical diagnosis and treatment of human granulocytotropic anaplasmosis.

Authors:  Johan S Bakken; J Stephen Dumler
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

2.  Increasing incidence of Ehrlichia chaffeensis and Anaplasma phagocytophilum in the United States, 2000-2007.

Authors:  F Scott Dahlgren; Eric J Mandel; John W Krebs; Robert F Massung; Jennifer H McQuiston
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

3.  DNA gyrase-mediated natural resistance to fluoroquinolones in Ehrlichia spp.

Authors:  M Maurin; C Abergel; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-08-11       Impact factor: 17.586

5.  Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis.

Authors:  R S Buller; M Arens; S P Hmiel; C D Paddock; J W Sumner; Y Rikhisa; A Unver; M Gaudreault-Keener; F A Manian; A M Liddell; N Schmulewitz; G A Storch
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

6.  A real-time combined polymerase chain reaction assay for the rapid detection and differentiation of Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Ehrlichia ewingii.

Authors:  Constance A Bell; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2005-11-02       Impact factor: 2.803

7.  Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease.

Authors:  S M Chen; J S Dumler; J S Bakken; D H Walker
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

Review 8.  Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment.

Authors:  J Stephen Dumler; John E Madigan; Nicola Pusterla; Johan S Bakken
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

9.  Prevalence of Ehrlichia muris in Wisconsin Deer Ticks Collected During the Mid 1990s.

Authors:  Sam R Telford Iii; Heidi K Goethert; Jenny A Cunningham
Journal:  Open Microbiol J       Date:  2011-05-04

Review 10.  Current applications and future trends of molecular diagnostics in clinical bacteriology.

Authors:  Jan Weile; Cornelius Knabbe
Journal:  Anal Bioanal Chem       Date:  2009-04-18       Impact factor: 4.142

View more
  11 in total

Review 1.  Human granulocytic anaplasmosis.

Authors:  Johan S Bakken; J Stephen Dumler
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

2.  Use of Routine Complete Blood Count Results to Rule Out Anaplasmosis Without the Need for Specific Diagnostic Testing.

Authors:  Sarah E Turbett; Melis N Anahtar; Vikram Pattanayak; Marwan M Azar; K C Coffey; George Eng; Joseph W Rudolf; Kent B Lewandrowski; Jason Baron; Eric S Rosenberg; John A Branda
Journal:  Clin Infect Dis       Date:  2020-03-03       Impact factor: 9.079

3.  Development of a TaqMan Array Card for Acute-Febrile-Illness Outbreak Investigation and Surveillance of Emerging Pathogens, Including Ebola Virus.

Authors:  Jie Liu; Caroline Ochieng; Steve Wiersma; Ute Ströher; Jonathan S Towner; Shannon Whitmer; Stuart T Nichol; Christopher C Moore; Gilbert J Kersh; Cecilia Kato; Christopher Sexton; Jeannine Petersen; Robert Massung; Christine Hercik; John A Crump; Gibson Kibiki; Athanasia Maro; Buliga Mujaga; Jean Gratz; Shevin T Jacob; Patrick Banura; W Michael Scheld; Bonventure Juma; Clayton O Onyango; Joel M Montgomery; Eric Houpt; Barry Fields
Journal:  J Clin Microbiol       Date:  2015-10-21       Impact factor: 5.948

4.  Evaluation of different nested PCRs for detection of Anaplasma phagocytophilum in ruminants and ticks.

Authors:  Jifei Yang; Zhijie Liu; Qingli Niu; Junlong Liu; Jingying Xie; Qiuyu Chen; Ze Chen; Guiquan Guan; Guangyuan Liu; Jianxun Luo; Hong Yin
Journal:  BMC Vet Res       Date:  2016-02-24       Impact factor: 2.741

5.  Pro-inflammatory immune responses are associated with clinical signs and symptoms of human anaplasmosis.

Authors:  Anna M Schotthoefer; Steven J Schrodi; Jennifer K Meece; Thomas R Fritsche; Sanjay K Shukla
Journal:  PLoS One       Date:  2017-06-19       Impact factor: 3.240

6.  Comparison of three nucleic acid-based tests for detecting <i>Anaplasma marginale</i> and <i>Anaplasma centrale</i> in cattle.

Authors:  Mamohale E Chaisi; Janine R Baxter; Paidashe Hove; Chimvwele N Choopa; Marinda C Oosthuizen; Kelly A Brayton; Zamantungwa T H Khumalo; Awelani M Mutshembele; Moses S Mtshali; Nicola E Collins
Journal:  Onderstepoort J Vet Res       Date:  2017-01-23       Impact factor: 1.792

7.  Evaluation of a Novel Multiplex High-Definition PCR Assay for Detection of Tick-Borne Pathogens in Whole-Blood Specimens.

Authors:  Blake W Buchan; Dean A Jobe; Michael Mashock; Derek Gerstbrein; Matthew L Faron; Nathan A Ledeboer; Steven M Callister
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

8.  Severe Anaplasmosis presenting as possible CVA: Case report and 3-year Anaplasma infection diagnosis data is based on PCR testing and serology.

Authors:  Yasser Eldaour; Rahman Hariri; Mohamed Yassin
Journal:  IDCases       Date:  2021-03-10

Review 9.  Epidemiological and Clinicopathological Features of Anaplasma phagocytophilum Infection in Dogs: A Systematic Review.

Authors:  Sarah El Hamiani Khatat; Sylvie Daminet; Luc Duchateau; Latifa Elhachimi; Malika Kachani; Hamid Sahibi
Journal:  Front Vet Sci       Date:  2021-06-23

10.  Surge in Anaplasmosis Cases in Maine, USA, 2013-2017.

Authors:  Susan P Elias; Jessica Bonthius; Sara Robinson; Rebecca M Robich; Charles B Lubelczyk; Robert P Smith
Journal:  Emerg Infect Dis       Date:  2020-02       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.